New Century Financial Group LLC Invests $1.09 Million in Royalty Pharma plc (NASDAQ:RPRX)

New Century Financial Group LLC acquired a new stake in shares of Royalty Pharma plc (NASDAQ:RPRX) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 35,908 shares of the biopharmaceutical company’s stock, valued at approximately $1,091,000.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC increased its position in shares of Royalty Pharma by 172.5% in the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,037 shares during the last quarter. Allworth Financial LP increased its holdings in shares of Royalty Pharma by 76.7% in the 4th quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 731 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Royalty Pharma by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 802 shares during the last quarter. Lindbrook Capital LLC grew its position in Royalty Pharma by 485.2% in the fourth quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 1,999 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Royalty Pharma by 4,335.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,750 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 2,688 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 0.2 %

Shares of Royalty Pharma stock traded up $0.04 on Thursday, hitting $25.92. The stock had a trading volume of 1,570,036 shares, compared to its average volume of 2,374,490. The stock’s 50-day simple moving average is $27.25 and its two-hundred day simple moving average is $28.45. Royalty Pharma plc has a one year low of $25.83 and a one year high of $31.66. The company has a quick ratio of 12.52, a current ratio of 12.52 and a debt-to-equity ratio of 0.62. The stock has a market cap of $15.49 billion, a price-to-earnings ratio of 19.34, a PEG ratio of 3.38 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. The firm had revenue of $568.00 million for the quarter, compared to analysts’ expectations of $671.45 million. Royalty Pharma had a net margin of 35.70% and a return on equity of 22.94%. During the same quarter in the previous year, the company earned $1.60 earnings per share. As a group, sell-side analysts predict that Royalty Pharma plc will post 4.03 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 17th were issued a $0.21 dividend. The ex-dividend date was Thursday, May 16th. This represents a $0.84 annualized dividend and a yield of 3.24%. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target for the company. in a research note on Monday, June 3rd. StockNews.com cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Finally, Bank of America lowered their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, April 12th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.